Home
IMMP
IMMP News

Latest Immutep Limited (IMMP) News on October 31, 2025

MT Newswires

11 days ago

Immutep Says its Mid-Stage Trial of Eftilagimod Alfa Meets Primary Endpoint of Tumor Hyalinization/Fibrosis

ASX Value Insights Duratec And Two More Stocks Possibly Below Fair Value

Simply Wall St.

17 days ago

ASX Value Insights Duratec And Two More Stocks Possibly Below Fair Value

MT Newswires

18 days ago

Immutep Completes Dosage Optimization Requirements for Potential Lung Cancer Immunotherapy

Immutep Announces Successful Completion of FDA Project Optimus Requirements

GlobeNewswire

18 days ago

Immutep Announces Successful Completion of FDA Project Optimus Requirements

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire

22 days ago

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

ASX Penny Stocks Spotlight: D3 Energy And Two Others To Watch

Simply Wall St.

25 days ago

ASX Penny Stocks Spotlight: D3 Energy And Two Others To Watch

ASX Value Stock Estimates Offering Opportunities In October 2025

Simply Wall St.

25 days ago

ASX Value Stock Estimates Offering Opportunities In October 2025

ASX Stocks That May Be Undervalued In October 2025

Simply Wall St.

a month ago

ASX Stocks That May Be Undervalued In October 2025

3 ASX Penny Stocks With At Least A$200M Market Cap

Simply Wall St.

2 months ago

3 ASX Penny Stocks With At Least A$200M Market Cap

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

GlobeNewswire

2 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

High Growth Tech Stocks in Australia July 2025

Simply Wall St.

4 months ago

High Growth Tech Stocks in Australia July 2025

ASX Penny Stocks Spotlight: Arafura Rare Earths And Two More To Consider

Simply Wall St.

4 months ago

ASX Penny Stocks Spotlight: Arafura Rare Earths And Two More To Consider

With 51% institutional ownership, Immutep Limited (ASX:IMM) is a favorite amongst the big guns

Simply Wall St.

4 months ago

With 51% institutional ownership, Immutep Limited (ASX:IMM) is a favorite amongst the big guns

High Growth Tech Stocks In Australia For June 2025

Simply Wall St.

4 months ago

High Growth Tech Stocks In Australia For June 2025

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

GlobeNewswire

4 months ago

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

Exploring Life360 And 2 Prominent High Growth Tech Stocks In Australia

Simply Wall St.

4 months ago

Exploring Life360 And 2 Prominent High Growth Tech Stocks In Australia

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

GlobeNewswire

5 months ago

Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

High Growth Tech Stocks in Australia Featuring Life360 and Two Others

Simply Wall St.

5 months ago

High Growth Tech Stocks in Australia Featuring Life360 and Two Others

MT Newswires

6 months ago

Immutep Says Efti Triple Combination Improves Response Rate in Non-Small Cell Lung Cancer

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

GlobeNewswire

6 months ago

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

MT Newswires

6 months ago

Immutep Reports 'Excellent' Median Overall Survival in Efti-Keytruda Combo Trial; Shares Rise

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

GlobeNewswire

6 months ago

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Immutep Quarterly Activities Report Q3 FY25

GlobeNewswire

6 months ago

Immutep Quarterly Activities Report Q3 FY25

Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire

7 months ago

Immutep to Participate in Upcoming Investor Conferences

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire

7 months ago

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

GlobeNewswire

7 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025

Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires

Insider Monkey

8 months ago

Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

Insider Monkey

9 months ago

Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?

Immutep Quarterly Activities Report Q2 FY25

GlobeNewswire

9 months ago

Immutep Quarterly Activities Report Q2 FY25

Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?

Insider Monkey

9 months ago

Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?

Insider Monkey

9 months ago

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

GlobeNewswire

9 months ago

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Simply Wall St.

10 months ago

Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company

Patient Enrolment Completed for INSIGHT-003

GlobeNewswire

10 months ago

Patient Enrolment Completed for INSIGHT-003

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

GlobeNewswire

10 months ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

GlobeNewswire

10 months ago

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep announces results from Cohort B of TACTI-003 trial

TipRanks

a year ago

Immutep announces results from Cohort B of TACTI-003 trial

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire

a year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

Fortune

a year ago

Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million

MT Newswires

a year ago

Sector Update: Health Care Stocks Lower Thursday Afternoon

MT Newswires

a year ago

Immutep Shares Rally Following Positive Phase 1 Trial Data of Efti Combination Therapy in Non-Small Cell Lung Cancer

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

GlobeNewswire

a year ago

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago

Simply Wall St.

a year ago

Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago

Immutep Quarterly Activities Report Q1 FY25

GlobeNewswire

a year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

GlobeNewswire

a year ago

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

MT Newswires

a year ago

Immutep Completes Recruitment for Early-Stage Trial of IMP761, Advances to Dose Escalation

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

GlobeNewswire

a year ago

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

a year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep concludes participant enrolment in Phase II breast cancer trial

Clinical Trials Arena

a year ago

Immutep concludes participant enrolment in Phase II breast cancer trial

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

GlobeNewswire

a year ago

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

MT Newswires

a year ago

Immutep Receives $2.5 Million R&D Tax Incentive From French Government

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

GlobeNewswire

a year ago

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

GlobeNewswire

a year ago

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

GlobeNewswire

a year ago

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

GlobeNewswire

a year ago

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

GlobeNewswire

a year ago

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

Both retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decrease

Simply Wall St.

a year ago

Both retail investors who control a good portion of Immutep Limited (ASX:IMM) along with institutions must be dismayed after last week's 10% decrease

Immutep to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q4 FY24

GlobeNewswire

a year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

GlobeNewswire

a year ago

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

MT Newswires

a year ago

Immutep Receives Dutch Regulatory Approval to Begin Human Testing of Potential Autoimmune Treatment

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

GlobeNewswire

a year ago

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Zacks

a year ago

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

MT Newswires

a year ago

Top Midday Gainers

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

Immutep Achieves 'Positive' Results From Cohort B of Phase 2B Cancer Trial; Shares Rise Pre-Bell

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

GlobeNewswire

a year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

GlobeNewswire

a year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

a year ago

Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

GlobeNewswire

a year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

MT Newswires

a year ago

Immutep Completes Stock Offering

Immutep successfully completes institutional placement and institutional component of entitlement offer

GlobeNewswire

a year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

MT Newswires

a year ago

Immutep, Merck Collaborate on Trial for Lung Cancer Therapy

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

GlobeNewswire

a year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years

Simply Wall St.

a year ago

Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years

MT Newswires

a year ago

Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

GlobeNewswire

a year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

GlobeNewswire

a year ago

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep Quarterly Activities Report Q3 FY24

GlobeNewswire

2 years ago

Immutep Quarterly Activities Report Q3 FY24

MT Newswires

2 years ago

Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Benzinga

2 years ago

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

GlobeNewswire

2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

GlobeNewswire

2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire

2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited (ASX:IMM): Is Breakeven Near?

Simply Wall St.

2 years ago

Immutep Limited (ASX:IMM): Is Breakeven Near?

11 Best ASX Stocks To Buy Now

Insider Monkey

2 years ago

11 Best ASX Stocks To Buy Now

Immutep Announces First Clinical Data from 90mg Dosing of Efti

GlobeNewswire

2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

Simply Wall St.

2 years ago

Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

10 Best Australian Stocks To Buy

Insider Monkey

2 years ago

10 Best Australian Stocks To Buy

Share on Social Networks: